BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food ...
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month ...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...
Revolution Medicines reported its first commercial quarter on Wednesday, posting $197.6 million in net product revenue for ...
IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial ...
CLN-049 is also being studied in a Phase 1/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and PD of IV-administered CLN-049 in ...
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients wi ...
HLB corporate identity [Financial News] HLB’s liver cancer drug is once again drawing attention after the schedule for its ...
11h
Earnings And Shelf Filing Might Change The Case For Investing In Provident Financial Services (PFS)
Provident Financial Services reported third quarter 2026 results with net interest income of US$208.01 million and net income ...
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI continues to ...
<?xml encoding="utf-8" ?> Revolution Medicines RVMD reported third-quarter financial results on Wednesday. The transcript ...
Arcus Biosciences (NYSE: RCUS) reported Q3 2026 revenue of $9 million, down from $26 million as Gilead collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results